Amanta Healthcare Share News - Latest Updates, Live News & More

Latest news about Amanta Healthcare

Amanta Healthcare begins manufacturing at new Steriport facility in Kheda 10 days ago

Amanta Healthcare has commenced manufacturing at its new Steriport facility. The facility is located at the company's Kheda campus. The development marks an operational milestone in the company's manufacturing expansion.

Amanta Healthcare shares web-link for FY26 annual report and AGM notice Aug 25, 2026

Amanta Healthcare revenue rises 5% in Q1FY27 as SteriPort expansion delays Aug 08, 2026

Amanta Healthcare reports Q1FY27 revenue of ₹694.5 lakh, PAT at ₹33.1 lakh Aug 07, 2026

Amanta Healthcare appoints Nilesh Punjabi to senior management Aug 05, 2026

More news about Amanta Healthcare

09Jul 26

Amanta Healthcare concludes investor meeting with ValPro Capital

Amanta Healthcare officials held a virtual investor meeting with ValPro Capital on July 9, 2026. The interaction involved sharing publicly available information, with no Unpublished Price Sensitive Information disclosed. The disclosure was made under Regulation 30 of the SEBI Listing Obligations Regulations.

02Jul 26

Amanta Healthcare discloses off-market share transfers worth ₹1,60,000

Amanta Healthcare disclosed off-market share transfers involving a promoter and a member of the promoter group executed on June 30, 2026. The transfer of 1,000 equity shares worth ₹1,60,000 was conducted via an inter-se mechanism. The company submitted the disclosures to BSE and NSE on July 1, 2026, under Regulation 7(2) of the SEBI (Prohibition of Insider Trading) Regulations, 2015.

23Jun 26

Promoter group member increases stake in Amanta Healthcare

Jitendrakumar Jashbhai Patel, a member of the promoter group, acquired 16,200 equity shares of Amanta Healthcare Limited through open market purchases on the NSE between June 16 and June 18, 2026. The transactions, valued at Rs. 24,29,680, increased his stake from 8.98% to 9.02%. The disclosure was made in compliance with SEBI (Prohibition of Insider Trading) Regulations, 2015.

19Jun 26

Amanta Healthcare promoter Bhavesh Patel increases stake to 16.31%

Amanta Healthcare Limited promoter Bhavesh Girishbhai Patel increased his shareholding to 16.31% by acquiring 4,635 equity shares on June 17, 2026. The market purchase on the NSE was valued at ₹6,96,730, excluding taxes and brokerage.

18Jun 26

Amanta Healthcare promoter sells shares worth Rs 7.86 lakh

Amanta Healthcare Limited disclosed that promoter group member Kirit Ambalal Desai sold 5,000 equity shares for Rs 7.86 lakh on the NSE on June 15, 2026. The sale reduced his holding from 2.92% to 2.91%. The company confirmed no derivatives trading occurred and filed the disclosure under SEBI PIT Regulations.

31May 26

Amanta Healthcare commissions 10.8 MWp solar plant for captive use

Amanta Healthcare commissioned a 10.8 MWp solar power plant at Village Baroda, Taluka Matar, District Kheda, on May 30, 2026. The plant will supply electricity for captive consumption at the company's Hariyala factory, aiming to reduce operational costs and enhance sustainability. The intimation was submitted under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

22May 26

Amanta FY26 PAT Rises 42% to INR 15 Cr

Amanta Healthcare Limited reported a 42% YoY increase in net profit to INR 15 Cr for FY26, with revenue from operations rising to INR 288 Cr. EBITDA stood at INR 63 Cr, maintaining a 22% margin, while the debt-to-equity ratio improved to nearly 1x. The company is expanding its SteriPort capacity to 12 crore bottles per year, operational by June 20, 2026, and expects EBITDA margins to improve to 24-25% with the commissioning of a 10.8 MW solar power project.

20May 26

Amanta Healthcare appoints auditors for FY 2026-27

Amanta Healthcare's Board has appointed M/s. Kashyap R. Mehta & Partners as Secretarial Auditor for a five-year term from FY 2026-27 to FY 2030-31, pending shareholder approval. Additionally, the firm re-appointed M/s. Parikh Shah & Associates as Internal Auditor and M/s Y S THAKAR & Co. as Cost Auditor for the financial year 2026-27.

20May 26

Amanta Healthcare revises CMD remuneration to ₹13.29 lakh

Amanta Healthcare's board approved revising the Chairman & Managing Director's remuneration to ₹13.29 lakh per month, up from ₹10 lakh, effective April 1, 2026. This change is subject to shareholder approval via a Special Resolution at the upcoming Annual General Meeting.

20May 26

Amanta Healthcare posts Q4 FY26 earnings call recording

Amanta Healthcare Limited has announced that the audio recording of its earnings conference call for the fourth quarter of the fiscal year 2026 is now available. Investors can access the recording on the company's website.

23Apr 26

Amanta Healthcare Clarifies Promoter Share Acquisition with Credit of Remaining 15,500 Shares

Amanta Healthcare Limited has clarified that the remaining 15,500 equity shares purchased by promoter Shri Bhavesh Patel on March 30, 2026, were credited to his demat account on April 17, 2026. This completes the acquisition of 28,800 shares, increasing his shareholding from 63,11,044 shares (16.25%) to 63,26,544 shares (16.29%). The company has requested stock exchanges to update their records with this revised information.

16Apr 26

Amanta Healthcare Limited Announces Resignation of Senior Management Personnel

Amanta Healthcare Limited announced the resignation of Shri Vimal Shrimali, AVP – HR & ADMIN, effective April 16, 2026, due to personal reasons. The company has notified stock exchanges BSE and NSE about this senior management change in compliance with SEBI regulations. Shrimali expressed willingness to assist with transition processes for smooth handover of responsibilities.

09Apr 26

Amanta Healthcare Completes Analyst Meeting and Site Visit at Kheda Facility

Amanta Healthcare Limited has successfully completed its scheduled analyst and institutional investor meeting on April 7, 2026, at its Kheda, Gujarat facility. The meeting included group discussions and site visits, with company officials sharing only publicly available information while ensuring no Unpublished Price Sensitive Information was disclosed, maintaining full compliance with SEBI regulations.

08Apr 26

Amanta Healthcare Limited Files SEBI Compliance Certificate for Quarter Ended March 31, 2026

Amanta Healthcare Limited submitted its quarterly compliance certificate to BSE and NSE for the quarter ended March 31, 2026, under SEBI regulations. The certificate, provided by registrar MUFG Intime India Private Limited, confirms proper handling of dematerialized securities and adherence to prescribed timelines. Company Secretary Nikhita Dinodia signed the April 8, 2026 submission, ensuring regulatory compliance with stock exchange requirements.

02Apr 26

Amanta Healthcare Limited Files Annual SEBI SAST Disclosures for FY 2025-26

Amanta Healthcare Limited filed annual disclosures under SEBI SAST Regulations for FY 2025-26 on April 2, 2026, with both BSE and NSE. The promoter group, led by Chairman & Managing Director Bhavesh G. Patel, declared no encumbrance on company shares during the financial year. The compliance filing was coordinated by Company Secretary Nikhita Dinodia, ensuring adherence to regulatory requirements under Regulation 31(4) of SEBI SAST Regulations, 2011.

01Apr 26

Amanta Healthcare Promoter Increases Stake Through Open Market Purchase of 28,800 Shares

Amanta Healthcare disclosed that promoter Bhavesh Girishbhai Patel acquired 28,800 equity shares worth ₹28,18,826 through open market purchases on March 27 and March 30, 2026. The transactions increased his shareholding from 62,97,744 shares (16.22%) to 63,26,544 shares (16.29%). The company filed the mandatory disclosure under SEBI Insider Trading Regulations on April 1, 2026, demonstrating regulatory compliance.

28Mar 26

Bandhan Mutual Fund Files SEBI Disclosure After Crossing 5% Stake in Amanta Healthcare

Bandhan Mutual Fund through its Small Cap Fund acquired 21,603 equity shares of Amanta Healthcare on March 25, 2026, increasing its holding from 4.9568% to 5.0124%. The fund filed mandatory SEBI disclosure under Regulation 29(1) of SAST Regulations 2011, with formal notification submitted to BSE on March 27, 2026.

26Mar 26

Amanta Healthcare Reports Insider Purchase of 15,675 Equity Shares by Director's Relative

Amanta Healthcare Limited disclosed that Ms. Dypal Jain, immediate relative to Director Shri Nitin Jain, purchased 15,675 equity shares through open market transactions between March 19-24, 2026, valued at ₹15.01 lakh. The transactions were executed on NSE and BSE exchanges, increasing her total shareholding to 15,676 shares (0.04% of equity capital). The company submitted the required SEBI insider trading disclosure on March 26, 2026.

27Feb 26

Amanta Healthcare Promoter Increases Stake Through Open Market Purchase

Amanta Healthcare Limited disclosed that promoter Bhavesh Girishbhai Patel acquired 48,151 equity shares worth ₹50.20 lakh through open market purchases on February 26-27, 2026. The transaction increased his shareholding from 62,49,593 shares (16.10%) to 62,97,744 shares (16.22%). The disclosure was made under SEBI Insider Trading Regulations with shares purchased through NSE market transactions.

16Feb 26

Amanta Healthcare Hosts Maiden Earnings Call, Outlines ₹150 Crore Revenue Expansion Plan

Amanta Healthcare held its first earnings conference call following Q3FY26 results, with management detailing major expansion plans including doubling SteriPort capacity and SVP line enhancement. The company projects ₹150 crore incremental revenue from these initiatives, targeting overall revenue of ₹400 crore by FY27, while implementing cost optimization through a 10.8 MW solar plant expected to save ₹9 crore annually.

10Feb 26

Amanta Healthcare Limited Announces Changes in Senior Management Personnel

Amanta Healthcare Limited announced changes in its senior management personnel effective February 10, 2026, with Board approval for the inclusion of Shri Urmil Oza as Senior Management Personnel and removal of Shri Shailesh Shah. Urmil Oza, Vice President - Engineering, brings 30 years of experience including 26 years with the company, specializing in production engineering, utility management, and regulatory compliance. The company has notified BSE and NSE about these changes in compliance with SEBI regulations.

02Feb 26

Amanta Healthcare Opens Special Window for Transfer and Dematerialisation of Physical Securities

Amanta Healthcare Limited has opened a special window for transfer and dematerialisation of physical securities from February 05, 2026 to February 04, 2027, following SEBI Circular dated January 30, 2026. The one-year window allows investors to re-lodge transfer deeds for securities sold or purchased prior to April 01, 2019 that were previously rejected due to document deficiencies. Investors can submit complete documentation to MUFG Intime India Private Limited, the company's Registrar and Transfer Agent based in Ahmedabad.

02Jan 26

Amanta Healthcare Corrects Solar Power Plant Capacity to 10.8 MWp in Revised Agreement

Amanta Healthcare Limited issued a correction regarding its solar power plant project with Zodiac Energy Limited, rectifying the capacity from an erroneously reported 10.8 KWp to the correct 10.8 MWp. The company re-executed the agreement on January 02, 2026, maintaining all other terms and conditions while confirming regulatory compliance under SEBI regulations.

14Nov 25

Amanta Healthcare Allocates Rs 3,030 Crore from IPO Proceeds for Expansion

Amanta Healthcare Limited has used Rs 3,030.02 lakhs from its IPO proceeds for the quarter ending September 30, 2025. The funds were primarily used for capital expenditure at its Gujarat facility, including manufacturing equipment and civil construction. The company still has Rs 9,569.98 lakhs available for further planned expansions. Amanta plans to commence a SteriPort Manufacturing Line in January 2026 and an SVP Manufacturing Line in January 2027, both located in Hariyala, Kheda, Gujarat. For Q2 FY2026, the company reported a total income from operations of Rs 7,095.80 lakhs and a net profit after tax of Rs 120.76 lakhs.

12Nov 25

Amanta Healthcare Reports Fund Utilization Deviation and Q2 FY2026 Financial Results

Amanta Healthcare Limited disclosed a deviation in IPO fund utilization due to GST payment changes, adjusting issue expenses and reducing general corporate purpose expenses. The company's Q2 FY2026 results show revenue growth to Rs. 7,088.73 lakhs, but a decrease in net profit to Rs. 120.75 lakhs compared to Q2 FY2025. Half-year performance improved with revenue at Rs. 13,619.44 lakhs and net profit at Rs. 471.47 lakhs. Balance sheet highlights include increased total assets of Rs. 48,831.55 lakhs and improved cash position of Rs. 9,196.41 lakhs as of September 30, 2025.

12Nov 25

Amanta Healthcare Reports Q2 Profit, Completes IPO Listing

Amanta Healthcare Limited reported Q2 FY2026 results with total income of Rs. 7,095.80 lakhs and net profit of Rs. 207.80 lakhs. For H1 FY2026, total income was Rs. 13,850.45 lakhs with net profit of Rs. 185.50 lakhs. The company completed its IPO, issuing 10 million shares at Rs. 126 each, raising Rs. 12,600 lakhs. Listing occurred on September 9, 2025, on BSE and NSE. IPO proceeds are allocated for new manufacturing lines and corporate purposes, with Rs. 3,030.02 lakhs utilized so far. PriceWaterhouseCoopers provided an unmodified review opinion on the financial results.

Amanta Healthcare

197.75

-4.03

(-2.00%)

1 Year Returns:+32.97%

Industry Peers

Sun Pharmaceutical

1,840.00

(-1.13%)

Divis Laboratories

9,322.00

(-1.23%)

Torrent Pharmaceuticals

4,965.50

(+0.72%)

Zydus Life Science

1,119.10

(+0.12%)

Cipla

1,366.00

(-0.53%)

Laurus Labs

1,969.00

(+1.23%)

Dr Reddys Laboratories

1,165.50

(+1.97%)

Aurobindo Pharma

1,679.80

(+0.68%)

Lupin

2,095.00

(+0.83%)

Mankind Pharma

2,280.00

(+1.86%)

Get More Market Insights with

Stock Rental via SLBM

About Scanx

We’re building Scanx - to help you express your trading & investing idea, to help you analyse the markets better.

Stock Markets are the true indicator of the growth of any country's economy. We are bullish on India, we are bullish on India's prospects to be one of largest economies of the world. We believe that Stock Markets provide an unique opportunity for all Indians to participate in the growth story of India. We are enabling the same for Indians.
As financial services are becoming more accessible, there is now a large set of Indians today who are financially aware and literate. They value time and seek high quality products & services. Most screening, trading, investing platforms available today are more or less similar to each other, and they have not evolved with time. While both traders & investors have gotten smart about how they make money and build wealth, as users they have continued to use the same products, features, and platforms that were available for years with little or no innovation.
We plan to change that - a technology-led and artificial intelligence enabled platform built for super traders and long term investors.

Disclaimer:

The data and information provided on this website is for general informational and research purposes only. While we strive to ensure that the content is accurate, up-to-date, and reliable, this platform utilizes artificial intelligence (AI) tools to generate, curate, and summarize information. As such, the content may occasionally contain errors, omissions, or outdated information. All users are therefore advised to cross verify the source of the data and information.
This website does not constitute professional, legal, financial, medical, or any other form of licensed advice. Users are encouraged to independently verify any information before relying on it, especially for decisions that may have legal, financial, or personal consequences.
The views, analyses, and summaries presented on this platform may be generated or assisted by AI and do not necessarily reflect the opinions of the website owners, operators, editors, or affiliates.
We make no warranties or representations, express or implied, regarding the completeness, accuracy, reliability, suitability, or availability of the information contained on this website. Any reliance you place on such information is strictly at your own risk.
This website may include links to third-party sources or content. We do not control or endorse the nature, accuracy, or availability of those external sites and are not responsible for any content or damages arising from their use.
By using this website, you acknowledge and agree that the use of AI-generated content involves inherent limitations, uncertainties and inaccuracies, and you accept full responsibility for how you interpret and use the information provided.
We reserve the right to modify, update, or remove content and this disclaimer at any time without prior notice.

Part of Raise Financial Services

SEBI Stock Broker Registration No: INZ000006031 | Depository Participant (CDSL) ID: IN-DP-289-2016 | SEBI Research Analyst Registration No: INH000023357 Exchange Membership No. : NSE: 90133 | BSE: 6593 | MCX: 56320

Registered Office: Unit No. 2201, 22nd Floor, Gold Medal Avenue, S.V. Road, Beside Patel Petrol Pump, Piramal Nagar, Goregaon West, Mumbai - 400104